ArticleCase reports in neurological medicine2026
UNC5A IgG in a Previously Reported CASPR2/LGI1-Negative VGKC-Associated Peripheral Nerve Hyperexcitability Syndrome: Long-Term Clinical and Electrophysiological Follow-Up.
Article in Case reports in neurological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune peripheral nerve hyperexcitability (PNH) syndromes are most commonly associated with antibodies against CASPR2 or LGI1. However, a subset of patients with clinically and electrophysiologically confirmed PNH remains negative for these established neuronal surface antibodies despite persistent VGKC antibody positivity. This report presents the long-term follow-up of a patient previously diagnosed with a Morvan-like autoimmune PNH syndrome following enteroviral infection. Serial neurophysiological studies demonstrated persistent motor axonal hyperexcitability, while treatment with intravenous immunoglobulin (IVIg) resulted in sustained clinical stabilization and substantial functional improvement. Additional research-based immunological analyses identified UNC5A IgG reactivity in serum using a live cell-based assay. UNC5A antibodies have previously been identified predominantly in the context of thymoma-associated neuromyotonia, including patients with Morvan syndrome and myasthenia gravis, often in association with CASPR2 antibodies. The identification of UNC5A IgG in a patient with electrophysiologically confirmed CASPR2/LGI1-negative PNH and persistent VGKC antibodies represents a hypothesis-generating association rather than evidence of a causal or pathogenic role. UNC5A IgG may represent an associated biomarker or a secondary immune phenomenon within a broader autoimmune response. This observation extends the clinical context in which UNC5A reactivity has been identified and supports further investigation of UNC5A and other candidate neuronal surface antigens in CASPR2/LGI1-negative PNH.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.